Showing results (1471-1480 of 1,515) with videos related to
Sort By:
Pageof 152
The Journal of Clinical Endocrinology and Metabolism|September 24, 2016
Bone Metastases and Skeletal-Related Events in Medullary Thyroid CarcinomaJian Yu Xu, William A Murphy, Denái R Milton, et al.Cell Reports|August 22, 2019
Mining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and α-Synuclein ProteotoxicityAmber Tariq, JiaBei Lin, Meredith E Jackrel, et al.The EMBO Journal|June 17, 2024
The SMC5/6 complex prevents genotoxicity upon APOBEC3A-mediated replication stressDylan F Fingerman, David R O'Leary, Ava R Hansen, et al.Journal of Clinical Microbiology|January 1, 1997
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungiA Espinel-Ingroff, M Bartlett, R Bowden, et al.The Journal of Pediatrics|March 5, 2022
Self-Reported Health Outcomes of Children and Youth with 10 Chronic DiseasesChristopher B Forrest, Julia Schuchard, Cortney Bruno, et al.JAMA Internal Medicine|September 2, 2025
Patient and Caregiver Outcomes of Health System, Community-Based, and Usual Dementia Care: A Prespecified Analysis of the Dementia Care Study (D-CARE) Randomized Clinical TrialDavid B Reuben, Alan B Stevens, Thomas M Gill, et al.Nature|June 4, 2025
Probing condensate microenvironments with a micropeptide killswitchYaotian Zhang, Ida Stöppelkamp, Pablo Fernandez-Pernas, et al.Neuro-Oncology|April 17, 2018
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastomaBenjamin M Ellingson, Dana T Aftab, Gisela M Schwab, et al.Cancer|December 7, 2018
A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosisDeepak Chellapandian, Melissa R Hines, Rui Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.Pageof 152